Dren Bio
San Carlos, United States · Founded 2019 · $131.0M raised
- Headquarters
- San Carlos, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- drenbio.com
- Total Funding
- $131.0M
- Last Round
- $65.0M Series BJun 2022
- Rounds
- 3
About
Dren Bio is a San Carlos, California-based clinical-stage biopharmaceutical company pioneering antibody therapeutics that deplete pathogenic cells and agents. Founded in May 2019 by CEO Nenad Tomasevic, the company develops bispecific antibodies that selectively engage effector cells to treat cancer and autoimmune diseases. In 2025, Sanofi agreed to acquire Dren Bio's lead CD20-directed bispecific antibody program DR-0201.
Summary
Dren Bio is a Biotech company based in San Carlos, United States, founded in 2019. It has raised $131.0M in total across 3 rounds, most recently a $65.0M Series B round in Jun 2022. Investors include 8VC, Pfizer Ventures and SR One.
Tech & App Stack
4 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jun 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.